A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma

The purpose of this study is to determine the side effects of TAB004 (investigational drug) when given alone or in combination with toripalimab (another investigational drug), to determine a reasonably safe amount (dose) of TAB004 (alone or with toripalimab) for treatment of patients with cancer, and to measure the amount of TAB004 and toripalimab in the blood. The word “investigational” means the study drug is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA).